Search by Drug Name or NDC
NDC 55513-0842-01 AIMOVIG 140 mg/mL Details
AIMOVIG 140 mg/mL
AIMOVIG is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amgen Inc. The primary component is ERENUMAB.
MedlinePlus Drug Summary
Erenumab-aooe injection is used to help prevent migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). Erenumab-aooe injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes migraine headaches.
Related Packages: 55513-0842-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Erenumab-aooe Injection
Product Information
| NDC | 55513-0842 |
|---|---|
| Product ID | 55513-842_9e3343fd-826c-41a4-a655-c71b4a651a16 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | AIMOVIG |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | erenumab-aooe |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 140 |
| Active Ingredient Units | mg/mL |
| Substance Name | ERENUMAB |
| Labeler Name | Amgen Inc |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761077 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 55513-0842-01 (55513084201)
| NDC Package Code | 55513-842-01 |
|---|---|
| Billing NDC | 55513084201 |
| Package | 1 SYRINGE in 1 CARTON (55513-842-01) / 1 mL in 1 SYRINGE |
| Marketing Start Date | 2019-03-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |